Ayurvedic herb Triphala for dog cancer

Commonly seen Dog Cancers are:-

1. Skin cancer - Skin tumors are very frequent in older aged dogs, but are less common in cats. Most skin cancer in cats is malignant, but in dogs they are frequently benign. All skin tumors should be examined by the veterinary doctor.
   
   
2. Breast cancer- 50 % of all breast tumors in dogs and eighty five percent of all breast tumors in cats are metastatic. Spaying your pet between six and twelve months of age will very much decrease the risk of breast cancer. Surgery is the treatment of choice for this type of cancer.
   
   
3. Head & Neck cancer  - Cancer of the mouth is widespread in dogs and less frequent in cats. Accumulations on the gums, bleeding, odor or difficult eating are signs to watch for. Many bulges are malignant, so early treatment is essential. Cancer may build up inside the nose of both cats and dogs. Bleeding from the nose, complexity breathing or facial swelling may happen.
   
   
4. Lymphoma – It is a common form of cancer in both dogs and cats. It is differentiated by growth of 1 or many lymph nodes in the body. A virus is the sources for most of these cancers in cats. Chemotherapy is commonly effectual in controlling this type of cancer.
   
   
5. Testicles cancer- these tumors are rare in cats and common in dogs. Many of these cancers are curable with surgery.
   
   
6. Abdominal Tumors – abdominal tumors inside the abdomen are frequent. It is hard to make an early diagnosis. Weight loss and abdominal extension are common signs of these tumors.
   
   
7. Bone cancer- Bone tumors are most frequently seen in large breed dogs and hardly ever in cats. The leg bones, near joints, are the most frequent sites. Persistent lameness and bump of the leg is an early sign of disease.

Ayurvedic Herb Triphala for Dog Cancer

Triphala – triphala is an herbal supplement that has been an herb of choice for treating cancers. Recent researches have supported this fact. Triphala enhances the immunity of the body thus helps in fighting against the cells causing cancer. Triphala since long has been a drug of choice of treating various disorders and diseases.

Triphala is an herbal formulation that is widely used in Ayurveda for the treatment of various ailments ⁽¹⁾. It consists of equal portions of dried and powdered fruits of three medicinal plants: Emblica officinalis, Terminalia chebula, and Terminalia belerica ⁽²⁾. Triphala is used to treat dental caries, anemia, jaundice, constipation, asthma, fever, chronic ulcers, inflammation, obesity and to promote immunity against infections such as pneumonia, tuberculosis, and AIDS.
It demonstrated antioxidant ^{(3) (2)}, anti-inflammatory ⁽⁴⁾, antibacterial ⁽⁵⁾, immunomodulatory ⁽⁶⁾, chondroprotective ⁽⁷⁾, antidiarrhoeal ⁽¹²⁾, and anticancer ^{(8) (1) (9) (13)} properties in vitro. These effects are due to the polyphenols and flavonoids present in its constituents. Triphala also showed hypolipidemic ⁽¹⁰⁾ and enteroprotective effects against methotrexate-induced damage in rats ⁽¹⁴⁾. However, these effects have not been tested in clinical trials.
A small study did not find significant difference between triphala and chlorhexidine mouthwashes when used for prevention of dental caries in children ⁽¹⁵⁾.

Triphala may cause gastrointestinal side effects.

Purported Uses

• Anemia
• Jaundice
• Constipation
• Asthma
• Infections
• Chronic ulcers
• Inflammation
• Obesity
• Hypercholesterolemia
• Cancer

Constituents

• Amla (Emblica officinalis)
• Myrobalan (Terminalia chebula)
• Belleric Myrobalan (Terminalia belerica)

Mechanism of Action

The exact mechanism of action is not known although the polyphenols and flavonoids are thought to be responsible for many of Triphala's effects. Gallic acid, a major polyphenol in Triphala, has antioxidant property ⁽¹¹⁾. Triphala also increased the reactive oxygen species (ROS) in breast cancer cells (MCF-7 and T-47D), resulting in apoptosis ⁽⁸⁾. Terminalia chebula, one of the components of Triphala, was shown to be a potent hyaluronidase and collagenase inhibitor that prevented degradation of cartilage ⁽⁷⁾. Triphala also protected mice from radiation-induced mortality ^{(2) (3)}. Oral administration of Triphala enhanced immune functions in rats ⁽⁶⁾.

1. Possible Adverse Reactions
   Intestinal gas, stomach upset, diarrhea
   
   
2. Herb-Drug Interactions
3. • Cytochrome P450 substrates: Triphala inhibits CYP3A4 and CYP2D6, and can affect the intracellular concentration of drugs metabolized by these enzymes ⁽¹⁶⁾.
   
   
   References

   1. Sandhya T, Lathika KM, Pandey BN, Mishra KP. Potential of traditional ayurvedic formulation, Triphala, as a novel anticancer drug. Cancer Lett 2006;231(2):206-14.
   2. Naik GH, Priyadarsini KI, Bhagirathi RG, et al. In vitro antioxidant studies and free radical reactions of triphala, an ayurvedic formulation and its constituents. Phytother Res 2005;19(7):582-6.
   3. Jagetia GC, Malagi KJ, Baliga MS, et al. Triphala, an ayurvedic rasayana drug, protects mice against radiation-induced lethality by free-radical scavenging. J Altern Complement Med 2004;10(6):971-8.
   4. Rasool M, Sabina EP. Antiinflammatory effect of the Indian Ayurvedic herbal formulation Triphala on adjuvant-induced arthritis in mice. Phytother Res 2007;21(9):889-94.
   5. Kumar MS, Kirubanandan S, Sripriya R. Triphala Promotes Healing of Infected Full-Thickness Dermal Wound. J Surg Res 2007.
   6. Srikumar R, Parthasarathy NJ, Devi SR. Immunomodulatory activity of triphala on neutrophil functions. Biol Pharm Bull 2005;28(8):1398-403.
   7. Sumantran VN, Kulkarni AA, Harsulkar A, et al. Hyaluronidase and collagenase inhibitory activities of the herbal formulation Triphala guggulu. J Biosci 2007;32(4):755-61.
   8. Sandhya T, Mishra KP. Cytotoxic response of breast cancer cell lines, MCF 7 and T 47 D to triphala and its modification by antioxidants. Cancer Lett 2006;238(2):304-13.
   9. Deep G, Dhiman M, Rao AR, Kale RK. Chemopreventive potential of Triphala (a composite Indian drug) on benzo(a)pyrene induced forestomach tumorigenesis in murine tumor model system. J Exp Clin Cancer Res 2005;24(4):555-63.
   10. Saravanan S, Srikumar R, Manikandan S. Hypolipidemic effect of triphala in experimentally induced hypercholesteremic rats. Yakugaku Zasshi 2007;127(2):385-8.
   11. Kaur S, Michael H, Arora S, et al. The in vitro cytotoxic and apoptotic activity of Triphala—an Indian herbal drug. J Ethnopharmacol 2005;97(1):15-20.
   12. Biradar YS, Singh R, Sharma K, et al. Evaluation of anti-diarrhoeal property and acute toxicity of Triphala Mashi, an Ayurvedic formulation. J Herb Pharmacother. 2007;7(3-4):203-12.
   13. Shi Y, Sahu RP, Srivastava SK. Triphala inhibits both in vitro and in vivo xenograft growth of pancreatic tumor cells by inducing apoptosis. BMC Cancer. 2008 Oct 10;8:294.
   14. Nariya M, Shukla V, Jain S, Ravishankar B. Comparison of enteroprotective efficacy of triphala formulations (Indian Herbal Drug) on methotrexate-induced small intestinal damage in rats. Phytother Res. 2009 Aug;23(8):1092-8.
   15. Tandon S, Gupta K, Rao S, Malagi KJ. Effect of Triphala mouthwash on the caries status. Int J Ayurveda Res. 2010 Apr;1(2):93-9.
   16. Ponnusankar S, Pandit S, Babu R, Bandyopadhyay A, Mukherjee PK. Cytochrome P450 inhibitory potential of Triphala—a Rasayana from Ayurveda. J Ethnopharmacol. 2011 Jan 7;133(1):120-5.

   
   
   
   
   
   

      

   Triphala is an Indian ayurvedic herb. Recently, it has been investigated for use as an anti-carcinogen. Triphala has also shown antioxidant and immune-enhancing benefits in test tube studies. It contains several compounds that are responsible for most of its therapeutic effects, including cancer prevention. If you have cancer, you should first consult with your doctor before taking triphala.

   Anti-proliferate Effect

   In a 2005 study conducted by G. Deep and colleagues at the Jawaharlal Nehru University in India, triphala has shown to help protect against the development of tumors in mice. The results of their studies have been published in the December 2005 issue of "Journal of Experimental & Clinical Cancer Research." It was found that the anti-proliferate effect of triphala is likely related to apoptosis, or programmed cell death.

   Antioxidant Activity

   Triphala is a rich source of natural antioxidants called polyphenols. Antioxidants inhibit the formation of free radicals, or unstable oxygen molecules, which cause oxidative damage to biomolecules such as lipids, proteins and nuclei acids, impairing normal cell functions. Cellular damage caused by free radicals contributes to increased susceptibility for cellular mutations eventually resulting in the initiation of cancer, the Memorial Sloan-Kettering Cancer Center notes.

   Breast Cancer

   T. Sandhya and colleagues at the Bhabha Atomic Research Center in India examined the effects of aqueous extracts of triphala on the growth and invasion of breast cancer cells. The results, published in the journal "Cancer Letters" in 2006, showed that triphala significantly decreased the growth of MCF-7 breast cancer cells. The analysis of this experiment further suggests that triphala extract might exert its anti-cancer effect by inducing apoptosis.

   Pancreatic Cancer

   Triphala induces apoptosis in human pancreatic cancer cells in vivo in the xenograft models. Scientists at the Texas Tech University Health Sciences Center reveal that triphala activates reactive oxygen species production. Because an accumulation of reactive oxygen species can lead to apoptotic cell death, triphala might inhibit pancreatic cancer cell growth, says Y. Shi, Ph.D., a professor of pharmaceutical sciences and cancer biology center at the Texas Tech University. The results of this experiment were first published in the "BMC Cancer" journal in October 2008.

   Triphala Research study
   Potential of traditional ayurvedic formulation, Triphala, as a novel anticancer drug.
   Cancer Lett. 2005;

   The cytotoxic effects of aqueous extract of Triphala, an ayurvedic formulation, were investigated on human breast cancer cell line (MCF-7) and a transplantable mouse thymic lymphoma (barcl-95). The viability of treated cells was found to decrease with the increasing concentrations of Triphala. On the other hand, treatment of normal breast epithelial cells, MCF-10 F, human peripheral blood mononuclear cells, mouse liver and spleen cells, with similar concentrations of Triphala did not affect their cytotoxicity significantly. The drug treatment was found to induce apoptosis in MCF-7 and barcl-95 cells in vitro as determined by annexin-V fluorescence and proportion of apoptotic cells was found dependent on Triphala concentration. MCF-7 cells treated with Triphala when subjected to single cell gel electrophoresis, revealed a pattern of DNA damage, characteristic of apoptosis. Studies on Triphala treated MCF-7 and barcl-95 cells showed significant increase in intracellular reactive oxygen species (ROS) in a concentration dependent manner. ROS increase was, however, found to be insignificant in MCF-10 F as well as in murine spleen and liver normal cells. In vivo, direct oral feeding of Triphala to mice (40mg/kg body weight) transplanted with barcl-95 produced significant reduction in tumor growth as evaluated by tumor volume measurement. It was also found that apoptosis was significantly higher in the excised tumor tissue of Triphala fed mice as compared to the control, suggesting the involvement of apoptosis in tumor growth reduction. These results suggest that Triphala possessed ability to induce cytotoxicity in tumor cells but spared the normal cells. The differential effect of Triphala on normal and tumor cells seems to be related to its ability to evoke differential response in intracellular ROS generation. The differential response of normal and tumor cells to Triphala in vitro and the substantial regression of transplanted tumor in mice fed with Triphala points to its potential use as an anticancer drug for clinical treatment.

The in vitro cytotoxic and apoptotic activity of Triphala--an Indian herbal drug.
J Ethnopharmacol. 2005.
A study on cytotoxic effect of acetone extract of Triphal" whose antimutagenicity has already been tested. The in vitro antimutagenic activity of Triphala --an Indian herbal drug. Food Chemistry and Toxicology 40, 47-54) was extended to test its cytotoxic effects on cancer cell-lines using Shionogi 115 (S115) and MCF-7 breast cancer cells and PC-3 and DU-145 prostate cancer cells as models. The results revealed that acetone extract of "Triphala" showed a significant cytotoxic effect on these cancer cell-lines and the effect was similar on all cancer cell lines used in this study. The major phenolic compounds in the most potent acetone extracts were isolated and purified. Structural analysis was conducted using spectroscopic techniques including mass spectroscopy, nuclear magnetic resonance (NMR) and infrared (IR) which showed gallic acid as the major component. The suppression of the growth of cancer cells in cytotoxic assays may be due to the gallic acid-a major polyphenol observed in Triphala.

1. 
   
   
   Read more: http://www.livestrong.com/article/494576-triphala-cancer/#ixzz2FYrd52eV

   
   
   
   

   • "BMC Cancer"; Triphala Inhibits both in vitro and in vivo Xenograft Growth of Pancreatic Tumor Cells by Inducing Apoptosis; Y. Shi; Oct. 2008
   • "Journal of Experimental & Clinical Cancer Research"; Chemopreventive Potential of Triphala (a Composite Indian Drug) on Benzo(a)pyrene Induced Forestomach Tumorigenesis in Murine Tumor Model System; G. Deep, et al.; Dec. 2005
   • "Cancer Letters"; Potential of Traditional Ayurvedic Formulation, Triphala, as a Novel Anticancer Drug; T. Sandhya, et al.; Jan. 2006
   • Memorial Sloan-Kettering Cancer Center; Triphala

   
   References

An Indian herbal remedy could one day be used to help fight pancreatic cancer, scientists hope.
A team at the University of Pittsburgh Cancer Institute found extracts of triphala slowed the growth of human pancreatic tumours grafted onto mice.
The findings, presented at the annual meeting of the American Association for Cancer Research, offer hope that one day a treatment might be developed.
But experts have warned the research is still at a very early stage.

Triphala triggered the cancerous cells to die off and significantly reduced the size of the tumours Professor Sanjay K Srivastava

Triphala is a herbal preparation used in the traditional Indian medicine system Ayurveda.
It contains the dried and powdered fruits of three plants, and it is said to ease intestinal-related disorders, promoting good digestion.


Anti-cancer properties
Previous studies have shown triphala to have an anti-cancer activity in cell cultures, and the new research found this effect also worked in mice fed the herb preparation, without damaging normal pancreatic cells.
The team fed mice grafted with human pancreatic tumours a triphala solution five days per week.
After four weeks they compared the tumour size and proteins contents of the tumours with those of a control group of mice that had not received the triphala.
They found that the tumours in triphala-treated mice were half the size of those in the untreated mice.
The also found the treated mice tumour cells had higher levels of proteins associated with apoptosis - the process by the which the body normally disposes of damaged, old of unneeded cells.
In cancer cells this process is often faulty, allowing the tumours to divide rapidly without any cells dying.


Professor Srivastava said: "Triphala triggered the cancerous cells to die off and significantly reduced the size of the tumours without causing any toxic side effects."
Further testing revealed that triphala had also activated tumour-suppressor genes, but did not negatively affect normal pancreatic cells.
Professor Srivastava said: "Our results demonstrate that triphala has strong anti-cancer properties given its ability to induce apoptosis in pancreatic cancer cells without damaging normal pancreatic cells.
 "With follow-up studies, we hope to demonstrate its potential use as a novel agent for the prevention and treatment of pancreatic cancer." 


http://www.ncbi.nlm.nih.gov/pubmed/21138390

Triphala, Ayurvedic formulation for treating and preventing cancer: a review.

Source

Research and Development, Father Muller Medical College, Mangalore, Kankanady, Karnataka, India. 

Abstract

BACKGROUND: Triphala (Sanskrit tri = three and phala = fruits), composed of the three medicinal fruits Phyllanthus emblica L. or Emblica officinalis Gaertn., Terminalia chebula Retz., and Terminalia belerica Retz. is an important herbal preparation in the traditional Indian system of medicine, Ayurveda. Triphala is an antioxidant-rich herbal formulation and possesses diverse beneficial properties. It is a widely prescribed Ayurvedic drug and is used as a colon cleanser, digestive, diuretic, and laxative. Cancer is a major cause of death, and globally studies are being conducted to prevent cancer or to develop effective nontoxic therapeutic agents. Experimental studies in the past decade have shown that Triphala is useful in the prevention of cancer and that it also possesses antineoplastic, radioprotective and chemoprotective effects

Triphala churna is a mild laxative, which cleanses and tonifies the gastro-intestinal tract. It is made from the three most important herbs in Ayurveda : Amalaki (Emblica Officinalis), Haritaki (Terminalia Chebula), and Vibhitaki (Terminalia Bellirica). Triphala is known as a cleaning agent, including a blood cleanser. The herb also has a high nutritional value, including high levels of vitamin C. Because of its high vitamin content, Triphala is often used as a food supplement like vitamins are in Western countries. In fact, the benefits of this herb are so well known that a well known Indian saying goes like this: "You do not have a mother? Don't worry, as long as you have Triphala in your life!".In recent years, a number of research studies have found new uses for this herb, including treatment for various forms of cancer. It is also found to have high antioxidant qualities, and is even useful for treatment against noise and stress induced conditions.^[3]

Benefits of Triphala Churna ^{[4][5][6]
(TRIPHALA CONTAINS THE BELOW HERBS)}
Amalaki or Amla (Emblica Officinalis)

• Is a fruit rich in vitamin C that builds immunity and an effective antioxidant that removes harmful toxins from the body.
• Amla helps to strengthen and nourish the lungs and the respiratory tract by removing mucus
• Vitamin C in Amla helps to maintain good reproductive health in both males and females, in whom it further helps to regulate menstrual cycles.
• Amla induces iron that aids blood circulation and maintains proper functioning of the heart.
• Its detox function helps in the formation of fresh tissues leading to a glowing skin.

Vibhitaki (Terminalia Bellirica)

• Vibhitaki acts as a blood purifier and curbs haemorrhage
• It is an internal cleanser removing harmful toxins and excess fats out of the body
• Its anti-viral and anti-bacterial abilities nurtures voice quality and improves eyesight
• Hair roots are strengthened and it enriches hair colour.

Haritaki (Terminalia Chebula)

• Haritaki has five rasas , or tastes, being sweet, sour, salty, bitter, pungentand astringent
• It stimulates the functioning of the digestive system and sensory organs
• It is an effective in combating piles, anaemia, gastro-intestinal problems and gall stones

One of the commonest and cheapest of Indian ayurvedic medical formulations - Triphala - is now emerging as one of the most potent anticancer agents.
This is the conclusion of scientists from a number of prominent research institutions in India as well as abroad, confirming some of the earlier studies conducted at Amala Cancer Research Center by Dr Ramadas Kuttan and associates since 2002.
In a study entitled ‘Potential of traditional ayurvedic formulation, Triphala, as a novel anticancer drug’ published in the January 2006 issue of Cancer Letters, scientists at the Radiation Biology and Health Sciences Division, Bhabha Atomic Research Centre, found that Triphala “possessed the ability to induce cytotoxicity (cell death) in tumor cells but spared the normal cells.
The scientists explain that the differential effect of Triphala on normal and tumor cells seems to be related to its ability to evoke differential response in intracellular ROS (Reactive Oxygen Species) generation. Conclusion: “The differential response of normal and tumor cells to Triphala in vitro and the substantial regression of transplanted tumor in mice fed with Triphala points to its potential use as an anticancer drug for clinical treatment.
Similarly, a December 2005 report in the Journal of Experimental and Clinical Cancer Research from the Radiation and Cancer Biology Laboratory at Jawaharlal Nehru University noted that Triphala was effective in reducing tumor incidences and increasing the antioxidant status of animals. The authors claim that theirs is “probably the first report on cancer chemopreventive potential of Triphala.” They also note “It was important to observe that Triphala was more effective in reducing tumor incidences compared to its individual constituents.
Another report from the Department of Botanical Sciences, Guru Nanak Dev University, Amritsar, found that "Triphala" showed a significant cytotoxic effect on cancer cell-lines and the effect was similar on all cancer cell lines used in this study.” The results, reported in the Journal of Ethnopharmacology in February 2005, reveal that the results may be due to the action of gallic acid-a major polyphenol observed in "Triphala". The same authors had previously reported that Triphala “had promising antimutagenic/anticarcinogenic potential. In February 2006, scientists from the Dr. A.L. Mudaliar Post-Graduate Institute of Basic Medical Sciences, University of Madras, Taramani Campus, reported supplementation with Triphala prevents the noise-stress induced changes in the antioxidant as well as cell-mediated immune response in rats. What this means is that Triphala is an anti stress agent. This study concludes that Triphala restores the noise-stress induced changes because of its antioxidant properties.
Antioxidant studies conducted at The Radiation Chemistry and Chemical Dynamics Division, Bhabha Atomic Research Centre in Trombay revealed that all three constituents of triphala are active and they exhibit slightly different activities under different conditions and the mixture, triphala, is expected to be more efficient due to the combined activity of the individual components. The findings were reported in the July 2005 issue of Phytotherapy Research. Two months later, scientists from BARC reported on the radio-protective ability of a component of Triphala.
Similar results were also reported from Kasturba Medical College, Manipal, in the Journal of Alternative and Complementary Medicine, when scientists claimed that “Triphala, an ayurvedic rasayana drug, protects mice against radiation-induced lethality by free-radical scavenging.” They concluded that “Triphala provided protection against both gastrointestinal and hemopoetic death.
In Phytotherapy Research, July 2004, scientists from Kasturba Medical College reported that certain traditional Indian polyherbal crude drugs, including Triphala, may be potent and novel therapeutic agents for scavenging of (Nitrous Oxide) NO, and thereby inhibit the pathological conditions caused by excessive generation of NO and its oxidation product, peroxynitrite. The scientists say these findings may also help to explain, at least in part, the pharmacological activities like rejuvenating, adaptogenic, anti-infection, anti-inflammatory, cardioprotective and neuroprotective activities of these traditional, clinically used non toxic drugs.

Respiratory system

• Respiratory infection - Triphala is an herb that is known for increasing the immunity of the body. Triphala acts as a powerful security checker and does not let any foreign particle to invade in the body and if by chance it gets into body, it strongly acts on it to eradicate that particle thereby protecting our body with its harmful after effects.
• Cough and cold – as mentioned earlier also that Triphala is very supportive in curbing any kind of infection in the body thereby it is helpful in withholding the conditions like cough and cold as it is also helpful in countering allergies.
• Accumulated mucus in the lungs and chest – as described earlier that Triphala has mucolytic properties thereby it is very helpful in expelling out the extra amount of mucus that some how gets accumulated in the chest and forms the grounds of infection.

• Anti-oxidant – Triphala is one of the powerful antioxidant. Its reference has been found in various ayurvedic texts. Triphala has a unique properties by which it is has the affinity to scavenges free radicals. It is very helpful in retarding the early aging process to make you young for ever. It also fills your body with new energies and enthusiasm that will make you and your body happy.

• Immunity – Triphala is extremely beneficial in increasing the immunity in the body and also helps in fighting any kind of infection that occurs in the body. It is helpful in production of various anti-bodies, T helper cells and lymphocytes that are helpful in fighting against any foreign invasion on our body.

Cancer – recent researches have proven that Triphala is highly effective in treating the cancer. These tests were conducted on mice. It does not let the abnormal division of the cells making them to perform normally. More researches are taking place to prove their effect on humans but it for sure that it has anti cancerous properties that make it a herb for future.

Loss of appetite – Triphala is a herbal formulation that is very effective in normalizing the digestion that is helpful in maintaining the normal amount of hunger desires in the body. It helps in promoting the decreased appetite.

Inflammation – Triphala is highly effective is reducing any kind of edematous growth internally as well as externally in the body and also is helpful in reducing inflammation.

Immuno-modulatory activities of Triphala on neutrophil functioning.

Biol-Pharm-Bull. 2005 Aug; 28(8): 1398-403

Immune activation is an effectual as well as defensive approach against rising infectious diseases. The immuno-modulatory behavior of Triphala (Terminalia chebula: Haritaki, Terminalia belerica: Bhibitaki and Emblica officinalis: Amalaki) were reviewed by testing the a variety of neutrophil functions like adherence, phagocytosis (phagocytic index (P.I) and avidity index (A.I)) and nitro blue tetrazolium (NBT) decrease in albino rats. In latest years much notice is being listening carefully on the immunological changes occur during stress. Noise (100 dB) stress for 4 h/d for 15 d, was engaged to alter the neutrophil purpose. The neutrophil function tests and corticosterone levels were approved out in 8 different groups of animals, namely controlled; Triphala, noise-stress, Triphala noise-stress, and matching immunized groups were used. Sheep RBC (SRBC 5 x 10(9) cells per ml) were used for immunizing the animals that fit in to immunized groups. In Triphala management (1 g/kg/d for 48 d), A.I was found to be considerably improved in the Triphala group, while the residual neutrophil functions and steroid levels were not distorted considerably. Though the neutrophil functions were considerably improved in the Triphala immunized group with a noteworthy reduction in corti-costerone level was seen. On contact to the noise-stress, the neutrophil functions were considerably concealed and followed by an important raise in the corticosterone levels were seen in both the noise-stress and the noise-stress immunized groups. These noise-stress-induced changes were appreciably prohibited by Triphala management in both the Triphala noise-stress and the Triphala noise-stress immunized groups. Hence our investigation has divulged that oral management of Triphala appears to rouse the neutrophil gathering in the immunized rats and stress induced repression in the neutrophil functions were considerably prohibited by Triphala.

This is because this herb (well fruit actually) set consists of the three fruits: Harada, Amla, and Bihara.

Amla is a sour tasting fruit that contains 20 times the amount of vitamin C than citrus fruits such as oranges. This is why this triad of fruits is used as a food supplement. Triphala, however has numerous other benefits besides its high vitamin content.

 The fruit Harada is what regulates your digestive system due to its laxative-like effects. This assists the body in ridding toxins from your liver and improving digestion. Triphala also has circulatory system benefits. Your circulation has the potential to improve when taking this herbal remedy, Additionally, triphala is known to lower blood pressure. According to Organic India, triphala is a blood cleanser, too.
The fruit Harada is an antispasmodic which means that it suppresses muscle spasms. The combination of the three fruits additionally is known to lower cholesterol, assist the body in recovering from stress and act as an anti-inflammatory especially for the stomach. Its anti-inflammatory properties are a result of the quercetin and vitamin C that is within this fruit mixture.

 Triphala is a relatively safe herb. Not many side effects are known to be caused by this antioxidant. Although at high levels it is known to cause diarrhea. 

  In conclusion, flavonoids of the flavone, flavonol, flavanone, and isoflavone classes possess antiproliferative effects in different cancer cell lines. Triphala being rich in these is a potent drug for cancer support. However, it remains for subsequent meticulous studies and investigations to determine which individual polyphenolic molecules can exert the most potent differentiating and growth inhibitory activity in cancer cells. Many people die of cancer without getting proper treatment either because of inaccessibility or unaffordability. So this project also focuses on the contribution of “triphala” in ameliorating the maladies suffered by those inflicted by the dreaded disease. This will help the humanity to eradicate one of the major causes of death. 



I GIVE LUCY 1 TRIPHALA CAPSULE PER DAY I BOUGHT FROM SWANSONVITAMINS.com (I just recently started this in late December 2012)

I also give her Ayurvedic herb Ashwagandha
 - It is also called 'Indian ginseng or winter cherry’ and is one of the most significant Ayurvedic herbs, supplementing with growth, health and energy. Customary use can help to nurture the blood and augment hemoglobin levels. Current studies have established that Ashwagandha has anti-tumor properties and can help to avert or slow the development of cancers. It is an effectual anti-inflammatory and has outstanding calming properties. This herb is often suggested as a tonic to help with recovery after illness.

I give Lucy 1 Ashwagandhaextract capsule per day from swansonvitamins.com

What should you ask your vet about dog nasal cavity or paranasal sinus cancer?

What should you ask your vet about dog nasal cavity or paranasal sinus cancer?

It is important to have frank, open discussions with your cancer care team. They want to
answer all of your questions, no matter how minor they might seem. For instance,
consider these questions:

· What kind of nasal cavity or paranasal sinus cancer does my dog have?
· Where is the cancer located?
· Has the cancer spread beyond the primary site?
· What is the stage of the cancer, and what does that mean in her case?
· Are there other tests that need to be done before we can decide on treatment?
· Are there other vets I need to see?
· How much experience do you have treating this type of dog cancer?
· What treatment choices do we have?
· What do you recommend and why?
· What is the goal of the treatment?
· What are the chances the cancer can be cured with treatment?
· How quickly do we need to decide on treatment?
· What should she do to be ready for treatment?
· How long will treatment last? What will it involve? Where will it be done?
· How would treatment affect her daily activities?
· What risks or side effects should we expect? How long are they likely to last?
· How will this treatment affect her appearance?
· What are our options if the treatment doesn't work or if the dog cancer recurs?
· What type of follow-up will I need after treatment?
· Where can I find more information and support?

In addition to these sample questions, be sure to write down some of your own. For
instance, you might want more information about recovery times so you can plan your
work or activity schedule.

Does Cimetidine or Tagamet Fight Cancer PART 2

 Cimetidine is a Common Heartburn Remedy that Complements Conventional Cancer Therapy 

Conventional cancer therapies do not always eradicate the cancer, leading patients to seek out adjuvant therapies that may confer additional benefits.

Although cimetidine was developed to relieve heartburn, acid indigestion, and sour stomach, numerous studies demonstrate that this readily available medication may offer powerful support in the fight against cancer. Unfortunately, many cancer patients and even oncologists remain unaware of the compelling evidence demonstrating its efficacy.

By preventing cancer metastasis (spread), slowing or halting tumor growth, and prolonging survival, cimetidine may serve as an important adjuvant therapy for people fighting colon cancer and other malignancies.

What Is Cimetidine?

Cimetidine, or Tagamet, reduces the production of stomach acid by binding with H2 receptors on the acid-secreting cells of the stomach lining. These receptors normally bind with histamine to produce stomach acid, which helps to break down food. By competing with histamine to bind with H2 receptors, cimetidine reduces the stomach's production of acid.

This mechanism of action accounts for cimetidine's use in managing gastroesophageal reflux disease (GERD), a condition marked by an excess of stomach acid. In fact, its use in treating gastric (stomach) disorders dates back several decades.

Anti-emetic drugs are used to prevent or treat nausea and vomiting. Before stronger anti-emetic drugs became available, cimetidine was prescribed to treat nausea associated with chemotherapy. As far back as 1988, scientists observed that colon cancer patients who had been treated with cimetidine had a notably better response to cancer therapy than those who did not receive cimetidine.1 Now, nearly 30 years of published research suggests that cimetidine may exert its most profound effects not as a heartburn remedy, but as an anti-cancer drug.

An Unexpected Anti-Cancer Agent

The first studies to hint at cimetidine's effectiveness against cancer were published in the late 1970s. Although scientists initially thought that cimetidine worked by enhancing immune function, later studies showed that cimetidine functions via several different pathways to inhibit tumor cell proliferation and metastasis

In a prospective, randomized, placebo-controlled study in 1988, 181 patients with gastric cancer received cimetidine (400 mg, twice daily) or placebo for two years or until death. Those given cimetidine had a significantly prolonged survival rate compared to the placebo group, particularly patients with more serious disease.1

In a 1994 study, just seven days of cimetidine treatment (IN HUMANS 400 mg twice daily for five days preoperative and intravenously for two days post-operative) in colorectal cancer patients decreased their three-year mortality rate from 41% to 7%. In addition, tumors in the cimetidine-treated patients had a notably higher rate of infiltration by lymphocytes, a type of white blood cell.2 These tumor-infiltrating lymphocytes, part of the body's immune response to the tumor, serve as a good prognostic indicator. When more tumor-infiltrating lymphocytes are present, the body is more capable of attack-ing and eliminating the tumor.

A report in the British Journal of Cancer examined findings of a collaborative colon cancer study conducted by 15 institutions in Japan. First, all participants had surgery to remove the primary colorectal tumor, followed by intravenous chemotherapy treatment. They were then divided into two groups: one group received 800 mg of oral cimetidine and 200 mg of fluorouracil (a cancer-fighting medication) daily for one year, while a control group received fluorouracil only. The patients were followed for 10 years. Cimetidine greatly improved the 10-year survival rate: 85% of the cimetidine-treated patients survived 10 years, while only 50% of the control group survived.3 Cimetidine produced the greatest survival-enhancing benefits in those whose cancer cells showed markers associated with the tendency to metastasize.

In just the last two years, several other studies have corroborated cimetidine's benefits for surviving colorectal cancer. For instance, in a Japanese study in 2006, colorectal cancer patients who received cimetidine following surgical removal of recurrent cancer had an improved prognosis compared to those treated with surgery only.4

A groundbreaking study reported in the International Journal of Oncology in 2006 confirms decades of research highlighting cimetidine's role as an important adjuvant cancer therapy. This study demonstrated that cimetidine may enhance survival in those undergoing conventional treatment for brain tumors.5 The most common primary brain tumors in adults and children, known as malignant gliomas (tumors that begin in the supportive cells of the brain or spinal cord), often fail to respond to chemotherapy, and are frequently fatal. Mice with tissue grafts of human glioblastoma cells that received both cimetidine and the chemotherapy drug temozolomide (Temodar®) demonstrated improved survival rates compared to those that received chemotherapy only. Cimetidine may thus prolong survival in people undergoing chemotherapy for the most prevalent type of brain tumor.

How Does Cimetidine Fight Cancer?

Since cimetidine's anti-cancer effects were first reported, scientists have proposed several hypotheses to explain how the drug works. Cimetidine's potential mechanisms of action include:

• modulating the body's immune response (immunomodulation)
• interfering with tumor growth
• inhibiting tumor cell migration and metastasis.

Cimetidine Modulates the Immune System

Histamine plays many roles in the body—contributing to allergic responses, regulating physiological function in the gut, and acting as a neurotransmitter. Histamine secretion also has the effect of suppressing the immune system.

Many cancers, particularly colorectal and breast tumors, secrete histamine.3,5,6 Histamine secretion also frequently occurs in response to surgical resection of colorectal cancers.6 In the tumor environment, histamine acts to suppress the immune response the body mounts to attack a tumor. This creates an immunosuppressive environment in the area of tumor growth and throughout the body, thus facilitating tumor growth.

Since cimetidine is a histamine receptor antagonist—that is, an agent that binds with a cell receptor without eliciting a biological response—it may help reduce immunosuppression caused by increased histamine levels in a tumor's environment.6,7 Administering cimetidine may enable the immune system to mount a more effective response, so that it can attack and potentially eliminate the tumor.

While histamine appears to stimulate the growth and proliferation of certain types of cancer cells,8 inhibiting histamine's action may be only one mechanism by which cimetidine fights cancer.9 Researchers have found evidence that cimetidine has many different effects on the immune system and the body's ability to respond to a tumor.

In 1972, for example, scientists discovered that T-suppressor cells in the immune system express receptors for histamine on their surface.10,11 T-suppressor cells accelerate the growth of tumors,12 and by activating these cells, histamine suppresses the immune response.13 Several studies have shown that cimetidine inhibits this immune suppression and helps restore a normal immune response.7,14-16 Compared to normal controls, gastric cancer patients also have higher levels of suppressor lymphocyte activity, and cimetidine treatment helps restore these levels to normal.17

During surgery, some cancer cells may be released into the bloodstream. A suppressed immune system may contribute to the ability of these residual cancer cells to escape immune surveillance and establish metastatic lesions.7,15,16 Cimetidine's ability to reverse immune suppression could thus help the immune system to remain alert to challenges such as spreading cancer cells.

In addition, many tumors are infiltrated with lymphocytes as a part of the body's immune response. The presence of tumor-infiltrating lymphocytes in a tumor indicates a better prognosis than for tumors that lack these white blood cells.2,17 With more tumor-infiltrating lymphocytes present, the body is more capable of attacking and eliminating the tumor. Administering cimetidine greatly elevated the proportion of colorectal cancers with tumor-infiltrating lymphocytes, probably by inhibiting the immunosuppressive function of histamine.18

Post-operative administration of cimetidine may also enhance the ability of cells known as peripheral lymphocytes to kill tumor cells, which is associated with enhanced disease-free survival.19 The presence of a lymphocyte response has been correlated with improved cancer survival.20 In a recent clinical study, cimetidine boosted peripheral blood lymphocytes and the tumor-infiltrating lymphocyte response. The authors concluded that administering cimetidine to gastrointestinal cancer patients several days before and after surgery may restore the diminished immune response often seen with cancer.21

A study from 2005 suggests cimetidine helps increase specific types of T-lymphocytes with protective attributes in the peripheral blood. Six healthy adults were given an 800-mg oral dose of cimetidine daily, and blood samples were collected at the study's onset and one, three, five, and seven days later. Cimetidine treatment was associated with an increase in white blood cells, specifically neutrophils (cells that fight bacterial invaders) and T-lymphocytes (which are involved in cell-mediated immunity). These results further suggest that cimetidine modulates cellular immunity and may be useful as an activator of tumor-specific immune response.22

In sum, cimetidine appears to support cellular immunity via several mechanisms, including blocking the immunosuppressive effect of histamine, inhibiting suppressor T-cell activity, increasing the number of tumor-infiltrating lymphocytes, and boosting the activity of peripheral blood lymphocytes.

Cimetidine: What You Need to Know

• Cimetidine is an over-the-counter, acid-blocking drug originally developed to treat heartburn, upset stomach, ulcers, and gastroesophageal reflux disease.
• In the 1980s, scientists noted that cancer patients who received cimetidine to manage chemotherapy-associated nausea experienced better outcomes, which led them to further investigate cimetidine's cancer-fighting effects.
• In 1985, Life Extension first called attention to cimetidine's promise as a novel anti-cancer therapy. Since then, more than 20 years of research has documented cimetidine's cancer-fighting effects.
• Used in conjunction with other cancer therapies, cimetidine has been found to significantly enhance cancer survival rates. Cimetidine works through several mechanisms of action, preventing immune suppression caused by tumor secretion of histamine, halting cancer growth, preventing angiogenesis, promoting cancer cell death, and averting often-fatal cancer metastasis.
• Further studies are needed to assess cimetidine's cancer-fighting abilities as both a sole therapeutic and an adjuvant cancer remedy.

Cimetidine Inhibits Tumor Growth

In addition to its effects in boosting immunity, cimetidine may help to slow or halt cancer by inhibiting the growth of several types of tumors.8

For example, in a cell-culture study of four colorectal tumor cell lines and four melanoma cell lines, histamine stimulated cell proliferation in a dose-dependent manner, while cimetidine reversed this effect.8,23 In another study, cimetidine inhibited the growth of human pancreatic cancer cells that had been grafted into immunodeficient mice.24 These findings suggest possible applications for cimetidine in colorectal, skin, and pancreatic cancers.

Scientists believe that cimetidine may prolong the survival of patients with various forms of cancer by inhibiting tumor-associated angiogenesis,25,26 the development of new blood vessels that tumors require to fuel their growth. In a 2005 report on cimetidine's effects on angiogenesis and tumor growth, cimetidine markedly reduced the growth (and production of new blood vessels needed to sustain the growth) of a grafted tumor in an animal model of colon cancer. These findings suggest that cimetidine suppresses tumor growth by inhibiting tumor-associated angiogenesis.25

Cimetidine may also fight cancer by promoting apoptosis (programmed cell death) in cancer cells. In a Chinese study from 2006, cimetidine induced apoptosis and halted cell division in human gastric cancer cells, leading the researchers to propose that cimetidine may have applications in treating gastric cancer.26

By shutting down the growth-stimulating effect of histamine, inhibiting angiogenesis, and promoting apoptosis, cimetidine thus appears to work via several mechanisms to arrest the growth of deadly tumors.

Cimetidine Inhibits Cancer Cell Metastasis

Most cancer deaths are caused not by primary tumors, but instead by metastases, or the secondary tumors that form when cells from the primary tumor spread to another location in the body. Cimetidine may prolong cancer survival by blocking the ability of cancer cells to metastasize to other locales in the body.

Adhesion molecules play a crucial role in many biological processes, such as wound healing, immune response, and cancer metastasis. These adhesion molecules are expressed on the surface of endothelial cells that line the blood vessels, which facilitates their adherence to other cells.

Adhesion molecules are intimately involved in the spread of cancer cells through the bloodstream to other locations where they will form secondary tumors. For example, when epithelial tumor cells enter blood vessels leading to the liver, they trigger the expression of an adhesion molecule called E-selectin in the liver blood vessel endothelium.27 This helps cancer cells form a secondary tumor in the liver.

Several types of cancer cells use Lewis antigens—carbohydrate formations on cell surfaces that can activate an immune response—to bind with E-selectin in blood vessel walls. Cimetidine may help prevent cancer cells from migrating throughout the body and forming distant metastases by blocking the expression of E-selectin.

When given to immunosuppressed mice with liver cancer, cimetidine successfully blocked tumor metastasis. Cimetidine appears to be unique in its ability to block cancer metastasis—similar H2-blocking drugs such as famotidine (Pepcid) and ranitidine (Zantac) did not produce a similar effect.

Thus it appears that cimetidine's ability to block cancer metastasis is independent of its ability to bind the H2 histamine receptor.28

Upon discovering cimetidine's ability to block cancer metastasis, researchers re-visited a study in which colorectal cancer patients were treated with cimetidine immediately before and after cancer surgery. They found cimetidine was particularly effective in enhancing survival for colorectal cancer patients with tumors expressing higher levels of two Lewis antigens.3 When the tumors were analyzed for Lewis antigen expression, patients who had tumors expressing Lewis antigens and who received cimetidine had a remarkable 10-year survival rate of 91%, compared to 34% for those not treated with cimetidine.

In 2003, Japanese researchers published findings indicating that cimetidine blocked the adhesion of gastric, esophageal, and breast cancer cells (all of which expressed a specific Lewis antigen) to epithelial cells expressing E-selectin. They concluded that cimetidine may be effective in preventing metastasis of these cancers.29

Cimetidine thus holds great promise in protecting against metastasis, the process that paves the way for cancer's often-fatal spread throughout the body.

Conclusion

Cimetidine's beneficial effects in helping to manage various cancers are well documented. For more than 20 years, scientists have accumulated evidence that this low-cost, readily available heartburn remedy fights cancer via several mechanisms of action, including blocking the immunosuppressive action of histamine, modulating the body's immune response, inhibiting angiogenesis, stimulating cancer cell death, and inhibiting cancer metastasis.

Cimetidine has not yet been approved by the FDA for use in treating cancer, and it remains unclear how its effects may enhance or synergize with other cancer treatments. However, cimetidine's demonstrated effects suggest that it may markedly suppress the ability of certain cancers—particularly colorectal cancers—to grow and metastasize, even when used as a sole therapy. Further studies are needed to evaluate and document cimetidine's efficacy both alone and in concert with other cancer-fighting regimens.

If your dog is on any medication, you should always read the PreCautions sheet.  Some meds cannot be combined with Tagamet (Cimetidine). 

____________________________________________________________________

     Dose for Mast Cell Tumors and growths & epuli in a 55-75 lb. dog example: 

1 tab 200 mg. Tagamet (Cimetidine) and

1 tab 25 mg. Benadryl (Diphenhydramine) caplet

twice a day for 3 weeks. 

 

With dogs who are terminal, the treatment is continued for the rest of the dog's life.

Some people have increased the Benadryl to 2 tabs per dose with no negative side affects and increased the shrinkage.  Each dog is different and you should decide your treatment accordingly. Always talk to your vet. Even when he doesn't like what you want to do just because you 'read it on the internet'. 

Research this yourself - you will see.

How This Works:

• 
  Mast Cell tumors are comprised of T1 and T2 cancer cells. 


• 
  Tagamet & Benadryl are over-the-counter drugs that encapsulate the T1 & T2 cancer cells. 


• 
  Tagamet encapsulates T1 cells and Benadryl encapsulates T2 cells by cutting off the blood and oxygen supply. 


• 
  This causes the cells to die which shrinks the tumors and puts the cancer into remission.


• 
  You may see one tumor, but it is very likely that other tumors may exist in the body that you cannot see.


• 
  When a tumor is surgically removed, you are only removing the one you can see.

Here are some dog owner who said it helps
http://www.veraboxers.com/cancer.htm

References

1. Tonnesen H, Knigge U, Bulow S, et al. Effect of cimetidine on survival after gastric cancer. Lancet. 1988 Oct 29;2(8618):990-2.

2. Adams WJ, Morris DL. Short-course cimetidine and survival with colorectal cancer. Lancet. 1994 Dec 24;344(8939-8940):1768-9.

3. Matsumoto S, Imaeda Y, Umemoto S, et al. Cimetidine increases survival of colorectal cancer patients with high levels of sialyl Lewis-X and sialyl Lewis-A epitope expression on tumour cells. Br J Cancer. 2002 Jan 21;86(2):161-7.

4. Yoshimatsu K, Ishibashi K, Yokomizo H, et al. Can the survival of patients with recurrent disease after curative resection of colorectal cancer be prolonged by the administration of cimetidine? Gan To Kagaku Ryoho. 2006 Nov;33(12):1730-2.

5. Lefranc F, Yeaton P, Brotchi J, Kiss R. Cimetidine, an unexpected anti-tumor agent, and its potential for the treatment of glioblastoma (review). Int J Oncol. 2006 May;28(5):1021-30.

6. Sieja K, Stanosz S, von Mach-Szczypinski J, Olewniczak S, Stanosz M. Concentration of histamine in serum and tissues of the primary ductal breast cancers in women. Breast. 2005 Jun;14(3):236-41.

7. Adams WJ, Morris DL, Ross WB, et al. Cimetidine preserves non-specific immune function after colonic resection for cancer. Aust NZ J Surg. 1994 Dec;64(12):847-52.

8. Adams WJ, Lawson JA, Morris DL. Cimetidine inhibits in vivo growth of human colon cancer and reverses histamine stimulated in vitro and in vivo growth. Gut. 1994 Nov;35(11):1632-6.

9. Siegers CP, Hiltl DM, Stich R. Cimetidine hemmt das Tumorzellwachstum. Therapie-woche. 1995 (36) 2110-4.

10. Melmon KL, Bourne HR, Weinstein J, Sela M. Receptors for histamine can be detected on the surface of selected leukocytes. Science. 1972 Aug 25;177(50):707-9.

11.   Nanda NK, Nath I. Characteristics of histamine receptors present on suppressor T cells in “healthy individuals.” Int J Immunopharmacol. 1985;7(4):587-95.

12. Nordlund JJ, Askenase PW. The effect of histamine, antihistamines, and a mast cell stabilizer on the growth of cloudman melanoma cells in DBA/2 mice. J Invest Dermatol. 1983 Jul;81(1):28-31.

13. Rocklin RE, Greineder DK, Melmon KL. Histamine-induced suppressor factor (HSF): further studies on the nature of the stimulus and the cell which produces it. Cell Immunol. 1979 May;44(2):404-15.

14. Griswold DE, Alessi S, Badger AM, Poste G, Hanna N. Differential sensitivity of T suppressor cell expression to inhibition by histamine type 2 receptor antagonists. J Immunol. 1986 Sep 15;137(6):1811-5.

15. Hansbrough JF, Zapata-Sirvent RL, Bender EM. Prevention of alterations in postoperative lymphocyte subpopulations by cimetidine and ibuprofen. Am J Surg. 1986 Feb;151(2):249-55.

16. Adams WJ, Lawson JA, Nicholson SE, Cook TA, Morris DL. The growth of carcinogen-induced colon cancer in rats is inhibited by cimetidine. Eur J Surg Oncol. 1993 Aug;19(4):332-5.

17. Harrison JC, Dean PJ, el-Zeky F, Vander ZR. From Dukes through Jass: pathological prognostic indicators in rectal cancer. Hum Pathol. 1994 May;25(5):498-505.

18. Morris DL, Adams WJ. Cimetidine and colorectal cancer—old drug, new use? Nat Med. 1995 Dec;1(12):1243-4.

19. Uchida A. Biological significance of autologous tumor-killing activity and its induction therapy. Cancer Immunol Immunother. 1993 Jul;37(2):75-83.

20. Adams WJ, Morris DL. Pilot study—cimetidine enhances lymphocyte infiltration of human colorectal carcinoma: results of a small randomized control trial. Cancer. 1997 Jul 1;80(1):15-21.

21. Li Y, Yang GL, Yuan HY, et al. Effects of perioperative cimetidine administration on peripheral blood lymphocytes and tumor infiltrating lymphocytes in patients with gastrointestinal cancer: results of a randomized controlled clinical trial. Hepatogastroenterology. 2005 Mar;52(62):504-8.

22. Asakage M, Tsuno NH, Kitayama J, et al. The effect of cimetidine mainly increases CD4+ cells of peripheral blood T lymphocytes. Gan To Kagaku Ryoho. 2005 Oct;32(11):1576-7.

23. Reynolds JL, Akhter J, Morris DL. In vitro effect of histamine and histamine H1 and H2RAs on cellular proliferation of human malignant melanoma cell lines. Melanoma Res. 1996 Apr;6(2):95-9.

24. Surucu O, Middeke M, Hoschele I, et al. Tumour growth inhibition of human pancreatic cancer xenografts in SCID mice by cimetidine. Inflamm Res. 2004 Mar;53 Suppl 1:S39-40.

25. Natori T, Sata M, Nagai R, Makuuchi M. Cimetidine inhibits angiogenesis and suppresses tumor growth. Biomed Pharmacother. 2005 Jan;59(1-2):56-60.

26. Jiang CG, Liu FR, Xu HM, Wu T, Gao J. Effects of cimetidine on the biological behaviors of human gastric cancer cells. Zhonghua Yi Xue Za Zhi. 2006 Jul 11;86(26):1813-6.

27. Khatib AM, Kontogiannea M, Fallavollita L, Jamison B, Meterissian S, Brodt P. Rapid induction of cytokine and E-selectin expression in the liver in response to metastatic tumor cells. Cancer Res. 1999 Mar 15;59(6):1356-61.

28. Kobayashi K, Matsumoto S, Morishima T, Kawabe T, Okamoto T. Cimetidine inhibits cancer cell adhesion to endothelial cells and prevents metastasis by blocking E-selectin expression. Cancer Res. 2000 Jul 15;60(14):3978-84.

29. Hayashi A, Kobayashi K, Imaeda Y, Matsumoto S. Cimetidine inhibits the adhesion of cancer cells with sialyl Lewis epitope onto the vascular endothelium. Gan To Kagaku Ryoho. 2003 Oct;30(11):1788-90.

CIMETIDINE TAGAMET FOR CANCER

CIMETIDINE (TAGAMET) FOR CANCER OF LUNG , SKIN, COLON, AND MELANOMA. 

Dogs with Mast Cell Tumors use this.

The first succesful use of cimetidine in treating cancer was at the the University of Nebraska[1]. Two patients with cancer were given cimetidine for stomach distress. Both had dramatic complete remissions from cancer. One had a squamous cell cancer in the neck that spread to the lung. The therapy was 1200 mg. of cimetidine daily. The other had a non-small cell cancer of the lung with a brain metastasis. This patient received steroids for the brain tumor and 600 mg. daily of cimetidine. The lung tumor immediately began to decrease in size. The brain tumor was surgically removed. Chest xray one year later showed no sign of malignancy. By 1982 it was recognized that cimetidine had the ability to inhibit suppressor T cells which thus permits lymphocytes to properly kill tumor cells.

Four patients with melanoma were treated with cimetidine in Ireland[2]. All four had widespread metsatases in internal organs, lung and liver. One young man had severe stomach distress which was treated with 1000 mg. daily of cimetidine. He had immediate regression of tumors and was able to return to work in two weeks. The three other melanoma victims were given 1000 mg. of cimetidine daily. Two had dramatic remissions of cancer and the third died. All these persons showed decrease of suppressor T cell function. All four also were on coumarin therapy (anticoagulation). Another six patients with melanoma from Sweden[3] were given interferon with no response. When cimetidine was added two had complete remissions, one had a partial remission, a fourth patient had no progression and the other two patients died.


Frequently colon cancer is found to be localized suggesting that surgery may be curative. The surgical procedure may cause a flood of microscopic cancer cells to be expressed into small blood and lymph channels for possible spread throughout the body. The stress of the surgical procedure itself has a profound negative effect on the immune system. For seven days following the operation there is a surge in suppressor T cells. These suppressor T cells tend to interfere with the body's need to localize and kill the extruded cancer cells. Cimetidine (Tagamet) has the ability to inhibit these suppressor T cells so that more of the embolized cancer cells get killed.

An Austrailian study[4] gave cimetidine (Tagamet) after surgery to one half of a large group of patients having colon cancer surgery. The cimetidine was taken for only 7 days. At 3 years the survival in the patients getting cimetidine was 93 % compared to a 59 % survival in the group not getting Tagamet. This is an astonishing result.

A Japanese study[5] at Nagoya University by Dr. Sumio Matsumoto gave all patients having colon cancer surgery 5- flourouracil a chemotherapy drug. One half these patients were also given 800 mg. of Tagamet beginning 2 weeks after surgery along with starting 5-flourouracil 150 mg. daily. Both Tagamet and 5 flourouracil were stopped at 1 year. Survival was reported at 3.9 years. In the patients with rectal cancer 100 % of those getting the additional Tagamet survived compared to only 53.3 % of those getting only 5- flourouracil. In the group of patients with colon cancer getting Tagamet 96.3 % survived compared to only 68 % in the group who got only 5-flourouracil. Amazingly the Tagamet was not started until two weeks after the operation so there was no inhibition of the suppressor cells during and immediately following the operation.

In the Australian study there appeared to be enhanced entry of lymphocytes into the tumors in subjects getting cimetidine 63.5 % compared to only 24 % in the control subjects. Additionally, cimetidine inhibits histamine which has immunosuppressive properties that could enhance tumor growth. It would appear that beginning the Tagamet one week before the surgery at about 800 mg. daily and continuing this for one year could possibly permit even more patients to avoid the spread of colon cancer. We strongly advise anyone having colon cancer surgery to get started on Tagamet before the surgery and stay on this therapy for one year. It is tragic that there probably has not been a single colon cancer patient in the United States who has benefited from this use of Tagamet in colon cancer surgery.


Footnotes:

1, The Lancet 1979 page 822-823

2, The Lancet 1982 11, page 328

3, New England Journal Of Medicine 1983 vol 308 page 591-592

4, The Lancet December 31, 1994 pp 1768-1769

5, The Lancet July 8, 1995 pp 115

PLEASE READ PART 2 TO THIS POST

http://dognasalcancertreatmentforlucy.blogspot.com/2013/01/does-cimetidine-or-tagamet-fight-cancer.html

http://www.self-helpcancer.org/cancertreatment2aa.htm

http://www.ncbi.nlm.nih.gov/pubmed/3328167 tagamet

http://www.ncbi.nlm.nih.gov/pubmed/2138376

http://www.petcarenaturally.com/blog/archives/301

http://www.petcarenaturally.com/blog/archives/date/2011/04

http://www.petcarenaturally.com/blog/archives/date/2011/03

http://www.petcarenaturally.com/handouts/same.pdf

http://www.tcvm.com/doc/TCVMNews2009SepR.pdf

http://miraclepooch.wordpress.com/2007/10/09/for-everyone-who-loves-their-animals/

http://www.shirleys-wellness-cafe.com/acancer.htm

http://www.caninecancer.com/alternatives.html